277 related articles for article (PubMed ID: 18842192)
1. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
[TBL] [Abstract][Full Text] [Related]
2. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
6. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Gensini GF; Gori AM; Dilaghi B; Rostagno C; Gaw A; Blanco-Colio LM; de Teresa E; Egido J; Farsang C; Leiter LA; Martineau P; Nozza A; Langer A;
Int J Cardiol; 2010 Jul; 142(3):257-64. PubMed ID: 19217176
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
8. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Martineau P; Gaw A; de Teresa E; Farsang C; Gensini GF; Leiter LA; Langer A;
Atherosclerosis; 2007 Mar; 191(1):135-46. PubMed ID: 16643923
[TBL] [Abstract][Full Text] [Related]
9. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
11. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J;
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
13. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
15. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
16. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
Ferrer-García JC; Pérez-Silvestre J; Martínez-Mir I; Herrera-Ballester A
Acta Diabetol; 2006 Nov; 43(3):75-8. PubMed ID: 17143784
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
[TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Huptas S; Geiss HC; Otto C; Parhofer KG
Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
[TBL] [Abstract][Full Text] [Related]
19. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Betteridge DJ; Gibson JM; Sager PT
Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
